文献速递类风湿关节炎

JAK抑制剂选择性差异:filgotinib与baricitinib、tofacitinib、upadacitinib的药效学比较

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
PubMed 文献 · Ann Rheum Dis · 2021-03-19

该体外及1期健康志愿者研究比较了filgotinib与baricitinib、tofacitinib、upadacitinib对JAK/STAT通路的抑制谱,发现filgotinib对JAK1依赖通路(IFNα/pSTAT5、IL-6/pSTAT1)的抑制强度与其他药物相当,但对JAK2/JAK3依赖通路抑制更弱,提示其疗效与安全性差异的药理学基础。

要点

  • Filgotinib对JAK1依赖的IFNα/pSTAT5和IL-6/pSTAT1抑制强度与对照JAKinibs相当。
  • Filgotinib对JAK2/JAK3依赖通路(如IL-2、IL-15、IL-4、IFNγ等)抑制最弱。
  • 1期健康志愿者离体药效学数据临床证实了filgotinib的JAK1选择性。

核心结论

  • Filgotinib对JAK1介导信号通的抑制与其他JAKinibs相似,但对JAK2和JAK3依赖通路的抑制更少,为其疗效与安全性差异提供了机制解释。

研究设计与样本

  • 体外研究:在健康供者和RA患者的外周血单核细胞及全血中,用流式细胞术检测不同细胞因子刺激后JAKinib对pSTAT的抑制。
  • 计算临床血浆药物暴露下免疫细胞中平均每日pSTAT抑制及抑制超过50%的时间。
  • 在1期健康志愿者离体刺激试验中验证上述药效学指标。

主要发现

  • JAKinib的效价取决于细胞因子刺激、pSTAT读数及细胞类型。
  • 在健康及RA血中,JAK1依赖通路(IFNα/pSTAT5、IL-6/pSTAT1)被所有JAKinibs最强抑制,其中filgotinib对JAK1通路选择性最高。
  • Filgotinib 200 mg每日一次对IFNα/pSTAT5和IL-6/pSTAT1的日均靶点抑制计算值与tofacitinib 5 mg每日两次、upadacitinib 15 mg每日一次、baricitinib 4 mg每日一次相当。
  • Filgotinib对JAK2依赖和JAK3依赖通路(包括IL-2、IL-15、IL-4、IFNγ、G-CSF、IL-12、IL-23、GM-CSF)的日均抑制最低。
  • 1期健康志愿者离体药效学数据临床证实了filgotinib的JAK1选择性。

临床怎么用

  • 临床选择JAKinib时,可参考药物对JAK1与JAK2/JAK3通路抑制谱的差异,结合患者疗效与安全性需求个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity. Filgotinib was compared with baricitinib, tofacitinib and upadacitinib to elucidate the pharmacological basis underlying its clinical efficacy and safety. METHODS: In vitro JAKinib inhibition of signal transducer and activator of transcription phosphorylation (pSTAT) was measured by flow cytometry in peripheral blood mononuclear cells and whole blood from healthy donors and patients with RA following cytokine stimulation of distinct JAK/STAT pathways. The average daily pSTAT and time above 50% inhibition were calculated at clinical plasma drug exposures in immune cells. The translation of these measures was evaluated in ex vivo-stimulated assays in phase 1 healthy volunteers. RESULTS: JAKinib potencies depended on cytokine stimulus, pSTAT readout and cell type. JAK1-dependent pathways (interferon (IFN)α/pSTAT5, interleukin (IL)-6/pSTAT1) were among the most potently inhibited by all JAKinibs in healthy and RA blood, with filgotinib exhibiting the greatest selectivity for JAK1 pathways. Filgotinib (200 mg once daily) had calculated average daily target inhibition for IFNα/pSTAT5 and IL-6/pSTAT1 that was equivalent to tofacitinib (5 mg two times per day), upadacitinib (15 mg once daily) and baricitinib (4 mg once daily), with the least average daily inhibition for the JAK2-dependent and JAK3-dependent pathways including IL-2, IL-15, IL-4 (JAK1/JAK3), IFNγ (JAK1/JAK2), granulocyte colony stimulating factor, IL-12, IL-23 (JAK2/tyrosine kinase 2) and granulocyte-macrophage colony-stimulating factor (JAK2/JAK2). Ex vivo pharmacodynamic data from phase 1 healthy volunteers clinically confirmed JAK1 selectivity of filgotinib. CONCLUSION: Filgotinib inhibited JAK1-mediated signalling similarly to other JAKinibs, but with less inhibition of JAK2-dependent and JAK3-dependent pathways, providing a mechanistic rationale for its apparently differentiated efficacy:safety profile.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021. PMID: 33741556. doi:10.1136/annrheumdis-2020-219012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。